Latest news with #thirteen
Yahoo
a day ago
- Business
- Yahoo
13 and Done: Nashville Superspeedway Breaks NASCAR Xfinity's Historic Viewership Run
13 and Done: Nashville Superspeedway Breaks NASCAR Xfinity's Historic Viewership Run originally appeared on Athlon Sports. The NASCAR Xfinity Series was on fire this year. For thirteen straight races, over a million people tuned in to watch every single event. That's the best streak the series has had in almost a decade and it showed just how much fans love what they're seeing on The CW. Advertisement But all good things come to an end. The Tennessee Lottery 250 at Nashville brought in 988,000 viewers, falling just short of that magic million mark. Still, it was the most-watched Xfinity race at Nashville since they started racing there again back in 2021. Here's the thing though – the numbers are still pretty amazing. Those first thirteen races averaged 1.176 million viewers, which is 20% higher than the same time last year. Back then, they were only getting about 978,000 viewers per race on average. NASCAR Xfinity Series drivers race at Nashville Nelles / The Tennessean / USA TODAY NETWORK via Imagn Images What's really helping is that The CW puts these races on free-to-air coverage instead of cable broadcast. More people can watch without paying extra and that's making a huge difference. It's the first time in the series' history that every race is free to watch. Advertisement Even with the streak ending, the Nashville numbers showed continued growth. The 988,000 viewers represented a 29% increase over the fourteenth race of 2024 at Sonoma Raceway, indicating that while the milestone run concluded, overall viewership remains robust and well above last year's pace. So yeah, the streak is over at thirteen races. But the bigger story here is that more people are watching NASCAR Xfinity than ever before and that's pretty exciting for the sport. Related: NASCAR Xfinity Series Hits Ratings Milestone With Rockingham Success This story was originally reported by Athlon Sports on Jun 4, 2025, where it first appeared.
The South African
03-05-2025
- Sport
- The South African
BIG NAME emerges for Orlando Pirates job - Not Pitso or Rulani
PSL heavyweights Rulani Mokwena and Pitso Mosimane are heavily linked with the Orlando Pirates job, washing out any noise of other candidates. It seemed set to be either of the two, but the latest whispers swirling from Mayfair point to another coach on their radar: Simba's Fadlu Davids. However, the former Orlando Pirates assistant coach is reportedly uninterested in a Soweto reunion. The Cape Town native is enjoying a stellar season with the Tanzanian giants, guiding them to within reaching distance of their first African title after defeating Stellenbosch 1-0 over two legs. A CAF Champions League finals awaits, and Morocco's RSB Berkane stands in their way of glory. It is perhaps this success, coupled with their title-challenging season – currently sitting thirteen points behind Young African with four games in hand – that Davids feels it's too soon to leave the seaside city of Dar es Salaam. 'Yes, it's true that Orlando Pirates wanted Davids back. It was not only Pirates, Raja (Casablanca) also wanted him, but he wanted to remain with Simba,' Citizen reported . 'He says he still has some unfinished business with Simba. He has done well at Simba and the fans love him so he wants to stay at the club.' It's no secret Orlando Pirates are vying for the services of Richards Bay frontman Yanela Mbuthuma. 'There are several players that the club is looking at for next season, but the first priority is the striking department and it's believed that they have identified Richards Bay United's Yanela Mbuthuma and the club is set to table an offer for him,' a source said. Let us know by leaving a comment below, or send a WhatsApp to 060 011 021 1. Subscribe to The South African website's newsletters and follow us on WhatsApp, Facebook, X and Bluesky for the latest news.
Yahoo
26-03-2025
- Business
- Yahoo
Asgard Therapeutics appoints immunology expert Shane Olwill as Chief Development Officer
Pioneering cancer immunology company Asgard strengthens leadership team as it progresses its lead asset AT-108 towards clinical trials Shane brings over two decades of expertise in immunology-driven drug discovery with a specialized focus on novel modalities AT-108 is a first-in-class, off-the-shelf cell reprogramming therapy that leads to personalized and potent anti-cancer immune responses LUND, Sweden, March 26, 2025 /PRNewswire/ -- Asgard Therapeutics, a privately held biotech company pioneering in vivo direct cell reprogramming for cancer immunotherapy, today announces the appointment of experienced immunology drug development specialist Shane Olwill as Chief Development Officer (CDO). Shane, who joins Asgard from Pieris Pharmaceuticals, now merged with NASDAQ-listed Palvella Therapeutics, will lead IND-enabling studies and clinical trials planning for Asgard's lead asset AT-108. AT-108 is a first-in-class, off-the-shelf cell reprogramming therapy that forces tumor cells to present their own tumor antigens, inducing a personalized immune response tailored to target each patient's cancer. Last September, Asgard had a key paper published in the high-impact journal Science which provided strong in vivo pre-clinical proof-of-concept for AT-108. During his thirteen years at Pieris, Shane played a pivotal role developing its diverse pipeline of clinical programs in immuno-oncology and respiratory diseases – progressing nine programs into the clinic. Prior to that he was Director of Research at AIM-listed Fusion Antibodies, building out its research team and establishing its technology platform. With over 60 intellectual property rights to his name, he is a recognized leader in drug development and a regular reviewer for prominent oncology and drug development journals. He holds a BSc in Biomedical Sciences and a PhD in Molecular Hematology from the University of Ulster, UK. Cristiana Pires, Co-founder and Chief Executive Officer of Asgard Therapeutics, said: "I'm delighted to welcome Shane as Asgard's CDO at this exciting time, as we progress our lead product AT-108 towards clinical trials and transition to a drug development company. Shane's skill set, derived from his extensive experience of pipeline development, particularly in immuno-oncology, is highly complementary to the other members of our team and will be of great benefit as we move forwards." Shane Olwill, Chief Development Officer of Asgard Therapeutics, said: "Asgard's in vivo cell reprogramming technology, based on the deep research and understanding of its founders, is a potentially transformative new form of cancer immunotherapy that is not only powerful but also indication-agnostic. I'm delighted to be joining the Company, whose science is backed by very strong data and whose team is supported by high calibre investors. I look forward to working to progress AT-108 towards the clinic and maximizing the potential of Asgard's wider platform." Martin Bonde, Chair of Asgard Therapeutics, said: "Shane will be instrumental as we further progress IND-enabling studies and CMC development for AT-108, to facilitate a seamless transition of the program to the clinic." Notes to Editors About Asgard Therapeutics Asgard Therapeutics is a privately held biotech company pioneering in vivo direct cell reprogramming for cancer immunotherapy. The company builds on ground-breaking and proprietary reprogramming technologies to develop gene therapy products designed to set in motion efficient and personalized immune responses. Backed by Johnson & Johnson Innovation – JJDC, Inc., RV Invest, Novo Holdings, Boehringer Ingelheim Venture Fund, and Industrifonden, Asgard Therapeutics aims to establish a pipeline of off-the shelf cancer immunotherapies that trigger personalized anti-cancer immune responses for the benefit of cancer patients in need. For more information, please visit: About AT-108 AT-108 is a first-in-class, off-the-shelf gene therapy that directly reprograms tumor cells into a rare subset of dendritic cells critical for mounting efficient cytotoxic T cell responses, cDC1 cells (conventional dendritic cells type 1). Reprogramming forces the tumor cells to present their tumor antigens, ultimately leading to a personalized anti-tumor immune response. It is based on a replication-deficient adenoviral vector that delivers three proprietary reprogramming factors into tumor cells, rewiring their gene expression signatures and thus "programming" them to become antigen-presenting cDC1-like cells. View original content: SOURCE Asgard Therapeutics
